Member Info for BertieBassett

Sorry Tyke ...

-- BB --

Balordo ...

-- BB --

Mojos were 1/2p back in the day ...

1 Mojo = 1 share in IBAI (after next fundraise)

The choice between a chewy sweet (strawberry or mint) which brings great happiness, vs a share in a disgracefully-run company ...?

Go Mojo!

-- BB --

... along ... or down .... :(

-- BB --

I believe (instinctively) that these lines in the RNS are a "buy me" message.

Phase 2 will need funding, and the designations themselves are very monetisable for the right purchaser ...

"The authors conclude that further investigation of the clinical efficacy of gallium maltolate in GBM is warranted and that this will require a statistically powered, Phase 2 trial.

Regulatory status

Gallium maltolate holds Fast Track, two Orphan Drug and two Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA). These designations relate to the regulatory development pathway and do not constitute any determination of efficacy by the FDA.

Reopening of the Expanded Access Programme

In response to continued interest from patients and clinicians, Imaging Biometrics intends to reactivate its Expanded Access Programme (EAP) to enrol up to 20 additional patients. The EAP provides a route for eligible patients to access investigational gallium maltolate outside of a clinical trial. As an investigational agent, GaM has not been approved by any regulatory authority; its safety and efficacy have not been established. Decisions regarding suitability for the EAP are a matter for a patient's treating physician."

When I first heard about IBAI, it felt like "Promised You a Miracle".

There was plenty of talk about a "Glittering Prize" ahead, and we were encouraged to "See the Lights" and believe that everything was "Alive and Kicking".

Sadly, what followed has felt more like "All the Things She Said" rather than tangible delivery. Lots of promises, plenty of presentations, but very little substance.

Perhaps "Once Upon a Time" there was a compelling vision. Today, many of us are still standing at the "Waterfront", waiting for the ship to come in.

As for the miracle? We're still waiting.

-- BB --

Imaging Biometrics has reached an important milestone with its IB Neuro software. A recent Phase II trial showed the technology can predict patient survival and works better than older manual methods. [1](https://www.londonstockexchange.com/stock/IBAI/imaging-biometrics-limited/company-page) This gives it strong credibility and suggests it could be used in real clinical settings.

The product also has clear practical value. It can show whether a treatment is working within weeks instead of months, helping doctors avoid ineffective and expensive therapies. [2](https://imagingbiometrics.com/our-solutions/ib-neuro/) This makes it easier to justify using and paying for the software.

The company has a straightforward plan to make money. It will sell to clinical trial sites and pharma companies, using both direct sales and partners. [1](https://www.londonstockexchange.com/stock/IBAI/imaging-biometrics-limited/company-page) It also aims to grow using its existing setup, which may limit the need for raising more funds.

Overall, this is a small but potentially high-upside company with a validated product and a clear path to revenue. However, it remains early-stage, with low current revenue and the usual risks of a very small-cap stock.

-- BB --

TB: "Imaging Biometrics enters this AGM with commercial momentum that is genuine and measurable."

IB Nimble™ 2 - Commercial Launch

QSMetric™ - GE HealthCare Distribution

Kirkstall Limited - Organ-on-a-Chip Platform

Gallium Maltolate - Phase 1 Publication - Following the successful completion of the Phase 1 clinical trial of oral gallium maltolate (GaM) in November 2025, preparation of the study results for journal submission is continuing. The Board expects submission in 2026 and will update shareholders once it has been made. The Group retains contractual rights to the Phase 1 data for regulatory and commercialisation purposes.

My take:

- As usual – not ONE figure ... profits ... deals ...

- "Imaging Biometrics enters this AGM with commercial momentum that is genuine and measurable." - so previous ones did not?

Hot air, aimed at keeping shareholders content.

If it were not for Tyke, I doubt we would have even received this!

Frankly, garbage.

-- BB --

Go Mike!

I am sure that he can put together a cogent and mathematically correct RNS also!

-- BB --

Gosh, Tyke – the word "profit" is not one I associate with IBAI – unless in a dream!!

-- BB --

Lost for words ...

-- BB --

... the IBAI Scheißshow continues ...

-- BB --

I wonder if one of the parties interested in the Phase 1 data is Trueride....?

Tyke, great work!!!

-- BB --

Tyke,

I emailed you this morning ...

-- BB --

Any investors out there with AJ Bell ...you can vote through the app.

I just have ..

-- BB --

I don't know whether any of you follow IBAI on LinkedIn – I do.

The output is frequent, interesting, informative, expressive and sometimes quite exciting.

But any potential investor or pharma exec would only have to dig down – even visit this site – to see that behind all the amazing science and possibilities is a company run by "amateurs".

'Trust' is the biggest word in any business, and the trust levels here are at zero.

It is such a shame.

-- BB --

I am quite sure this is not the first time that an IQAI/IBAI RNS has had to be amended ... and I am quite sure it will not be the last.

Spelling mistakes I can cope with, BUT getting figures wrong is simply unforgivable ... this is a business ...

Oh wait, maybe it's just a bank ...

-- BB --

It's 0.05 pence

• one-twentieth of a penny

• five hundredths of a penny

Mistake or is this really happening

-- BB --

It's NOT 1/2 a pence ...

** fundraise may be on the way ** (see below)

This is essentially an accounting and share-structure change, not an immediate change in the company’s value.

Imaging Biometrics Limited is proposing a “share sub-division” (also called a stock split).

Current structure:

Each ordinary share has a nominal/par value of £0.01 (1 penny).

Proposed structure:

Each ordinary share would instead have a nominal/par value of £0.0005.

The important line is:

“without altering the total of 246,709,789 shares outstanding.”

That means:

The number of shares you own does not change.

The total number of shares in issue does not change.

Your percentage ownership does not change.

The company’s market value does not automatically change.

So what is actually changing?

Only the “nominal value” (sometimes called face value or par value) attached to each share in the legal company records.

Example:

Before:

1 share = nominal value £0.01

After:

1 share = nominal value £0.0005

This is mostly a technical/legal restructuring.

Why companies do this:

Common reasons include:

Creating more flexibility for future fundraising.

Making the capital structure more suitable for growth or acquisitions.

Reducing the nominal value so new shares can be issued at lower prices without legal complications.

Preparing for future corporate actions.

What it does NOT necessarily mean:

It does not automatically mean the company is worth more.

It is not automatically dilution.

It is not automatically positive or negative.

The wording is slightly unusual because many share subdivisions increase the number of shares (e.g. 1 share becomes 10 shares). Here, they explicitly state the total shares outstanding will remain the same, suggesting this is primarily a reduction in nominal/par value rather than a traditional investor-facing stock split.

The AGM on 3 June 2026 is where shareholders vote on approving it.

Common reasons:

Insider filing technicalities

Executives/directors sometimes receive:

stock grants,

vesting adjustments,

dividend reinvestments,

compliance corrections,

account transfers.

These can generate Form 4 filings showing 1-share transactions. They may simply be bookkeeping entries rather than meaningful buys.

Testing or account verification

Brokerages, transfer agents, or automated trading systems occasionally use 1-share transactions to:

test settlement systems,

verify accounts,

activate trading permissions,

reconcile holdings.

Maintaining insider status

In some cases, an executive may buy a token amount to:

establish ownership,

maintain a reporting relationship,

demonstrate nominal alignment with shareholders.

A 1-share purchase has almost no financial significance unless the share price is extremely high.

Automated dividend reinvestment rounding

Dividend reinvestment plans (DRIPs) can occasionally round fractional holdings into whole shares, producing tiny transactions.

Optics / signalling

Rarely, insiders buy very small amounts as a public confidence signal. However, markets usually ignore tiny purchases because conviction is judged by:

total value purchased,

number of insiders buying,

whether purchases are open-market buys,

whether purchases are unusually large relative to salary/net worth.

Ten separate 1-share buys are generally less meaningful than:

one insider buying £50k+ worth of shares, or

multiple executives buying substantial amounts within 30 days.